Mallinckrodt Announces Journal Publication of Real-World Data on Acthar® Gel (repository corticotropin injection) to Treat Symptomatic Sarcoidosis in African American and Non-African American Patients

/PRNewswire/ -- Mallinckrodt plc, a global specialty pharmaceutical company, today announced the publication of findings from a retrospective chart review of...

Related Keywords

United States ,Dublin ,Ireland ,San Francisco ,California ,New York ,Americans ,American ,Derek Belz ,Mary Mcgowan ,Data Sciences ,Green Room Communications ,Mallinckrodt Pharmaceuticals ,American College Of Chest Physicians ,American Thoracic Society Annual International Conference ,Foundation For Sarcoidosis Research ,American Medical Association Physician Masterfile ,Drug Administration ,Acthar Gel ,African Americans ,African American ,Clinical Risk ,Thoracic Society Annual International Conference ,Therapeutic Advances ,Respiratory Disease ,Important Safety Information ,George Wan ,Vice President ,Evidence Generation ,Chief Executive Officer ,Sarcoidosis Research ,Physician Assessment ,Prescribing Information ,Important Safety ,Specialty Brands ,Specialty Generics ,Annual Report ,Non African Americans ,Symptomatic Sarcoidosis ,Patient Medical ,Ther Clin Risk ,Corticotropin Injection ,Advanced Symptomatic Sarcoidosis ,Retrospective Analysis ,Ther Adv Res ,Humana Press ,Sarcoidosis Epidemiology ,American College ,Accessed February ,Clinical Course ,Large White ,Black Cohort ,Sarcoidosis Vasc Diffuse Lung ,Mallinckrodt Plc ,